Prognostic value of peripheral blood inflammation-based markers in metastatic pancreatic cancer
Sun Jing, Shi Youwu, Jia Jun, Yang Ying, Sun Zhiwei, Du Feng, Yu Jing, Xiao Yanjie, Zhang Xiaodong
2022, 43(2):
299-304.
doi:10.3969/j.issn.1006-7795.2022.02.023
Asbtract
(
117 )
PDF (1827KB)
(
56
)
References |
Related Articles |
Metrics
Objective To evaluate significance of the inflammation-based prognostic markers, including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), albumin (ALB) and combined inflammation-based markers in metastatic pancreatic cancer. Methods The clinical data of 50 patients with metastatic pancreatic cancer admitted to VIP-Ⅱ Department of Peking University Cancer Hospital from July 2012 to October 2020 were collected retrospectively. Receiver operating characteristic (ROC) curve analysis were performed to determine the cut-off values of NLR, LMR, PLR and prognostic nutritional index (PNI). The accuracy of the prognostic indicators were evaluated by area under curve(AUC). The prognostic significance of the clinical characteristics and inflammation-based markers were evaluated by univariate and multivariate analysis. Results In 50 patients with metastatic pancreatic cancer, the median overall survival was 7.2 months (95%CI:3.568-10.699). The optimal cut-off of inflammation-based markers were: NLR=4.5 (AUC=0.840, 95%CI:0.732-0.948, P<0.001), PLR=138 (AUC=0.671, 95%CI:0.517-0.826, P=0.038), LMR=4.0 (AUC=0.873, 95% CI:0.770-0.975, P<0.001), ALB=41.5(AUC=0.726, 95% CI:0.582-0.870, P=0.006), respectively. Univariate and multivariate analysis showed that NLR≥4.5 (HR=11.936, 95%CI:4.571-31.169, P<0.001), PLR≥138 (HR=2.246, 95%CI:1.045-4.828, P=0.038), ALB<41.5 g/L (HR=3.214, 95%CI:1.463-7.060, P=0.004) were independent risk factors; LMR≥4 (HR=0.336, 95%CI:0.165-0.687, P=0.003) was an independent protective factor. NLR_ALB, PLR_ALB and LMR_ALB were independent prognostic indicators, and the higher the score, the worse the prognosis. Conclusion Peripheral blood inflammation-based marker NLR, LMR, PLR and ALB can be used as prognostic indicators for metastatic pancreatic cancer, the combined inflammation-based markers will promote simple and rapid prognosis assessments and has a certain clinical application prospect.